Journal article icon

Journal article

Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis.

Abstract:

BACKGROUND AND AIMS: Pilot studies with visilizumab, a humanised monoclonal antibody to CD3, suggest efficacy for corticosteroid-refractory ulcerative colitis (UC). A placebo-controlled trial was warranted. METHODS: A randomised, double-blind, placebo-controlled study evaluated the efficacy of visilizumab induction treatment in 127 patients with severely active UC despite treatment with ≥5 days of intravenous corticosteroids. Patients received placebo or visilizumab 5μg/kg intravenously on d...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1136/gut.2009.205443

Authors


Sandborn, WJ More by this author
Colombel, JF More by this author
Frankel, M More by this author
Lowder, JN More by this author
Expand authors...
Journal:
Gut
Volume:
59
Issue:
11
Pages:
1485-1492
Publication date:
2010-11-05
DOI:
EISSN:
1468-3288
ISSN:
0017-5749
URN:
uuid:2c6e0732-ec9a-4c74-83be-2e045d3bbe01
Source identifiers:
112212
Local pid:
pubs:112212

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP